Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Politics

FDA phasing out some animal testing in ‘win-win’ for ethics and public health: commissioner

by April 10, 2025
April 10, 2025

— The Food and Drug Administration is phasing out an animal testing requirement for antibody therapies and other drugs in favor of testing on materials that mimic human organs, the FDA announced on Thursday. 

‘For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,’ FDA Commissioner Martin A. Makary, said in comment provided to Fox News Digital. 

 ‘By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices. It is a win-win for public health and ethics.’ 

The phase-out focuses on ending animal testing in regard to researching monoclonal antibody therapies, which are lab-made proteins meant to stimulate the immune system to fight diseases such as cancer, as well as other drugs, according to the press release. 

Instead, the FDA will encourage testing on ‘organoids,’ which are artificially grown masses of cells, according to the FDA’s press release obtained by Fox Digital. 

‘The FDA will promote the use of lab-grown human ‘organoids’ and organ-on-a-chip systems that mimic human organs – such as liver, heart, and immune organs – to test drug safety. These experiments can reveal toxic effects that could easily go undetected in animals, providing a more direct window into human responses,’ the press release says. 

The FDA will also encourage the use of AI while testing drugs, including building computer modeling that can predict a drug’s behavior, Fox Digital learned. 

The phase-out will include updating its guidelines to recognize research conducted on organoids and through AI.

‘Companies that submit strong safety data from non-animal tests may receive streamlined review, as the need for certain animal studies is eliminated, which would incentivize investment in modernized testing platforms,’ the FDA explained in its press release. 

The FDA is slated to also work with fellow federal agencies, such as the National Institutes of Health, the National Toxicology Program and the Department of Veterans Affairs, to ‘accelerate the validation’ of the new testing standards and will hold a public workshop later this year to further discuss the matter. 

‘For patients, it means a more efficient pipeline for novel treatments. It also means an added margin of safety, since human-based test systems may better predict real-world outcomes. For animal welfare, it represents a major step toward ending the use of laboratory animals in drug testing. Thousands of animals, including dogs and primates, could eventually be spared each year as these new methods take root,’ Makary said. 

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Mexican drug lord convicted in killing of DEA agent Enrique ‘Kiki’ Camarena is freed
next post
Musk says DOGE set to top $150B in fraud savings in FY 2026

You may also like

Democrat Mary Peltola doubts results of GOP’s House...

January 6, 2023

Happy 247th Birthday US Marines!

November 10, 2022

Gaza humanitarian aid port likely to take approximately...

March 9, 2024

BREAKING: Maricopa County Creates “Ministry Of Truth” To...

September 28, 2022

TIME Person of the Year – Ukrainian President...

December 14, 2022

Millions spent by Biden on COVID ‘vaccine hesitancy’...

March 14, 2025

Angry Turks And Talking Turkey About Ukraine In...

November 15, 2022

Trump amends executive order raising China tariffs to...

March 4, 2025

5 mistakes that doomed Kamala Harris’ campaign against...

November 8, 2024

GOP Senator Calls For Investigation Into Joe Biden’s...

December 15, 2022

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Mitchell Geisler on Listening, Leadership and Business Growth

      August 23, 2025
    • 10 key takeaways from DOJ’s release of Ghislaine Maxwell’s Epstein interviews

      August 23, 2025
    • Jackson’s scathing dissent levels partisan charge at colleagues after high-profile ruling

      August 23, 2025
    • Starmer accused of betraying farmers as British food pledge stalls

      August 22, 2025
    • Fed rate cut looms after Powell’s Jackson Hole speech

      August 22, 2025
    • Tariff “Inclusion” Process Comes with High Costs, Absurd Outcomes, and Extra Cronyism

      August 22, 2025

    Categories

    • Business (8,858)
    • Investing (2,235)
    • Politics (16,465)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved